CytomX Therapeutics, Inc. (NASDAQ:CTMX) Position Raised by Fmr LLC

Fmr LLC boosted its position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 17.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 284,307 shares of the biotechnology company’s stock after purchasing an additional 41,949 shares during the period. Fmr LLC owned approximately 0.36% of CytomX Therapeutics worth $335,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CTMX. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of CytomX Therapeutics by 10.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after buying an additional 26,373 shares in the last quarter. US Bancorp DE acquired a new position in CytomX Therapeutics during the third quarter worth about $40,000. Acadian Asset Management LLC raised its position in CytomX Therapeutics by 1.4% in the second quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock worth $3,324,000 after acquiring an additional 37,739 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in CytomX Therapeutics by 96.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 40,309 shares during the last quarter. Finally, Forefront Analytics LLC boosted its position in shares of CytomX Therapeutics by 206.7% during the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 43,176 shares in the last quarter. 67.77% of the stock is owned by institutional investors.

CytomX Therapeutics Stock Down 0.9 %

Shares of CytomX Therapeutics stock opened at $1.09 on Friday. CytomX Therapeutics, Inc. has a 12-month low of $0.83 and a 12-month high of $5.85. The firm has a market capitalization of $85.30 million, a PE ratio of 6.41 and a beta of 1.07. The stock’s fifty day moving average is $1.06 and its 200-day moving average is $1.21.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $33.43 million for the quarter, compared to the consensus estimate of $18.92 million. During the same quarter in the previous year, the company earned $0.04 EPS. Analysts expect that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Monday, November 11th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.